AstraZeneca’s Camizestrant Gets EU Approval for Advanced Breast Cancer

Precision Oncology’s Breakthrough: Camizestrant’s EU Green Light

The CHMP’s approval of Etcamah (camizestrant) is not just another cancer drug recommendation—it’s a validation of how far molecularly targeted therapies have come in Europe. The drug, developed by AstraZeneca, is designed to degrade estrogen receptors in tumors harboring ESR1 gene mutations, which are often acquired as resistance mechanisms in patients who’ve previously failed aromatase inhibitors. Until now, this subgroup had limited options beyond chemotherapy.

What makes this approval significant isn’t just the science, but the regulatory strategy behind it. The CHMP’s decision reflects a broader shift in how the EU evaluates oncology drugs: no longer are sponsors treating the European pathway as an afterthought. As The Clinical Trial Vanguard notes, the EU’s Clinical Trials Regulation—fully applicable since January 31, 2022—has forced sponsors to design trials with molecular precision in mind. Camizestrant’s approval wasn’t an accident; it was the result of protocols locked years ago, anticipating today’s regulatory landscape.

The Rare Disease Gambit: Jascayd for Fibrosis Patients

The same CHMP meeting also delivered a conditional marketing authorization for Jascayd (nerandomilast), a first-in-class treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). These diseases, characterized by irreversible lung scarring, have long been regulatory orphans—until now. The CHMP’s decision is a direct response to the unmet need: IPF patients typically die within three to five years of diagnosis, and existing therapies offer only marginal benefits.

Jascayd’s approval is particularly notable because it arrives after years of regulatory inertia in the fibrosis space. The drug’s mechanism—a phosphodiesterase-4 inhibitor—targets inflammation at its source, a departure from the antifibrotic agents (like nintedanib and pirfenidone) that have dominated the field. The CHMP’s conditional approval, which allows for accelerated review based on promising but not yet definitive data, signals a willingness to take calculated risks in areas where patients have few options.

Indication Extensions: The Hidden Story Behind the Numbers

While the headlines focus on new approvals, the CHMP’s May 2026 meeting also included 13 indication extensions—a figure that, at first glance, might seem like routine administrative work. But as The Clinical Trial Vanguard argues, these extensions are anything but. Each represents a pivotal trial that survived full scientific scrutiny, often years in the making. For sponsors, this means the EU is not just a backwater for late-stage filings—it’s a primary battleground where first-to-market advantages can still be won.

Consider the case of Ablymico (liraglutide), now approved for weight management—a hybrid application that repurposed existing diabetes data alongside new evidence. Or Colchicine AGEPHA Pharma, cleared for secondary prevention in coronary disease patients. These aren’t incremental tweaks; they’re strategic pivots that reflect how the CHMP is increasingly willing to reward sponsors who think beyond single-indication approvals.

What This Means for Pharma: The EU as a Regulatory Leader

The numbers tell the story. In 2024, the EMA recommended 114 medicines for approval, including 46 new active substances and 15 orphan drugs. If the May 2026 session is any indication, the agency is on track to match or exceed those figures this year. For pharma executives watching from the sidelines, the message is clear: The EU is no longer a secondary market.

Take Roche’s Avastin (bevacizumab), for example—a drug already approved for multiple cancers but now under scrutiny for metastatic breast cancer and gastric cancer indications. While not part of the May CHMP meeting, recent reporting suggests the agency is moving toward broader approvals in oncology, a trend that aligns with the May session’s focus on expanded use of existing therapies. The implication? The EU is not just keeping pace with the U.S. FDA; in some cases, it’s setting the pace.

• Design for the EU first. The gap between protocol lock and regulatory outcome is where most companies lose time. The CHMP’s May decisions prove that trials designed with molecular precision—and aligned with the EU’s Clinical Trials Regulation—can deliver faster outcomes than waiting for FDA approval.
• Think beyond single indications. The 13 indication extensions in May show that the CHMP rewards sponsors who invest in real-world evidence and hybrid applications. A drug approved for diabetes might later gain weight-management approval—not because it’s a new molecule, but because the data package was built with future expansions in mind.

The Road Ahead: What’s Next for EU Drug Approvals?

The CHMP’s May 2026 output isn’t just a snapshot—it’s a blueprint for how the EU will shape global drug development in the coming years. With eight new approvals, 13 expanded indications, and a growing emphasis on precision medicine, the agency is sending a clear signal: The future of oncology—and rare diseases—is being written in Brussels.

For patients, the immediate impact is greater access to targeted therapies. For pharma, it’s a reminder that the EU’s regulatory pathway is no longer a secondary filing strategy—it’s a primary battleground. The question now isn’t if the next breakthrough will come from the CHMP, but when.

One thing is certain: the May 2026 meeting wasn’t just another CHMP session. It was a watershed moment—one that will be studied in regulatory strategy meetings for years to come.